Abstract:BackgroundStimulator of interferon genes (STING) has emerged as a crucial and promising target in tumor immunotherapy in recent years. Its agonists play a vital role in activating both innate and adaptive immune responses to combat cancer. Currently, STING agonists are primarily administered through intratumoral or intravenous injection, with only a few could be administered by orally. Therefore, orally available STING agonists are urgently needed to be developed.Approach and resultsBased on previous structure-activity relationship (SAR) studies, we made a structure modification to MSA-2 by replacing the carbonyl group with a difluoromethylene to get a new compound 202 (C202) that exhibited better plasma exposure and oral bioavailability than MSA-2. Thus, we conducted extensive pharmacological evaluations to understand its effects. C202 demonstrated the ability to activate various human STING isoforms and murine STING protein, showcasing a potent and specific activation of the STING signalling pathway at cellular level. In diverse immunocompetent mouse models representing both 'cold' and 'hot' tumors, C202, whether administered intratumorally or orally, displayed broad-spectrum anti-tumor activity. Encouragingly, it induced complete tumor regression in several tumor models of mice and stimulated immune memory effects, contributing to long-term immune response against cancer. Additionally, our investigations into the impact of C202 on the tumor microenvironment found that it enhanced the anti-tumor response of both innate and adaptive immune systems, bolstering the immune-mediated fight against tumors. Furthermore, we made an intriguing observation regarding C202's synergistic effects. It was found to enhance the anti-tumor activity of chemotherapy drug gemcitabine and the angiogenesis inhibitor AL3810, which provide potential combination therapies in future translational studies.ConclusionsOur research highlights C202 as a novel STING agonist with durable anti-tumor activity that can be administered orally, presenting a promising candidate for cancer immunotherapy. C202 specifically activates various STING isoforms and its downstream signalling, and exhibited high oral bioavailability and plasma exposure and displayed broad-spectrum anti-tumor activity either by local or oral administration. C202 activated both innate and adaptive anti-tumor immunity, and importantly it induced complete tumor regression and immune memory,C202 exerts synergistic effects with chemotherapy (gemcitabine) or angiogenesis inhibitor (AL3810) in anti-tumor. # image

Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy

Abstract 2116: VPS34 inhibitor SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

A novel STING agonist with systemic and durable anti-tumour activity

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

Combination of STING agonist with anti-vascular RGD-(KLAKLAK)2 peptide as a novel anti-tumor therapy

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Abstract 5587: STING and TLR 7/8 Agonist combination can improve immune checkpoint blockade therapy efficiency

Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer

Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors

Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma

Targeting STING signaling for the optimal cancer immunotherapy

A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy

Abstract 667: Inhibition of protein-protein interaction between STING and TRIM29 is a new approach to enhance anti-tumor immune response

VPS34-IN1 inhibits cap-mediated translation and synergizes with STING to drive type-I IFN expression in human plasmacytoid DCs

495P Intrinsic STING of CD8+T Cells Regulates Self-Metabolic Reprogramming and Exerts Anti-Tumor Effects

A hierarchically acidity-unlocking nanoSTING stimulant enables cascaded STING activation for potent innate and adaptive antitumor immunity

STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy